295 related articles for article (PubMed ID: 15011974)
1. Human papillomavirus detection: verification with cervical cytology.
Matthews-Greer J; Rivette D; Reyes R; Vanderloos CF; Turbat-Herrera EA
Clin Lab Sci; 2004; 17(1):8-11. PubMed ID: 15011974
[TBL] [Abstract][Full Text] [Related]
2. A peer comparison program for the quality assurance of human papillomavirus DNA detection using the Digene Hybrid Capture II/SurePath method shows excellent analytic interlaboratory correlation.
Kuebler DL; Illingworth A; Blenc AM; Wilbur DC
Cancer; 2007 Oct; 111(5):339-43. PubMed ID: 17879373
[TBL] [Abstract][Full Text] [Related]
3. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
4. Age-specific detection of high risk HPV DNA in cytologically normal, computer-imaged ThinPrep Pap samples.
Cibas ES; Hong X; Crum CP; Feldman S
Gynecol Oncol; 2007 Mar; 104(3):702-6. PubMed ID: 17150245
[TBL] [Abstract][Full Text] [Related]
5. Hybrid capture as a means of detecting human papillomavirus DNA from liquid-based cytology specimens: a preliminary evaluation.
Callaghan J; Karim S; Mortlock S; Wintert M; Woodward N
Br J Biomed Sci; 2001; 58(3):184-9. PubMed ID: 11575742
[TBL] [Abstract][Full Text] [Related]
6. Very low human Papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based Pap tests.
Zhao C; Elishaev E; Yuan KH; Yu J; Austin RM
Cancer; 2007 Oct; 111(5):292-7. PubMed ID: 17879368
[TBL] [Abstract][Full Text] [Related]
7. Efficiency of the hybrid capture 2 HPV DNA test in cervical cancer screening. A study by the French Society of Clinical Cytology.
de Cremoux P; Coste J; Sastre-Garau X; Thioux M; Bouillac C; Labbé S; Cartier I; Ziol M; Dosda A; Le Galès C; Molinié V; Vacher-Lavenu MC; Cochand-Priollet B; Vielh P; Magdelénat H;
Am J Clin Pathol; 2003 Oct; 120(4):492-9. PubMed ID: 14560561
[TBL] [Abstract][Full Text] [Related]
8. High-risk human papillomavirus DNA testing: a marker for atypical glandular cells.
Saqi A; Gupta PK; Erroll M; Babiac A; Blackmun D; Mansukhani M; Vazquez M
Diagn Cytopathol; 2006 Mar; 34(3):235-9. PubMed ID: 16470857
[TBL] [Abstract][Full Text] [Related]
9. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.
Wright TC; Schiffman M; Solomon D; Cox JT; Garcia F; Goldie S; Hatch K; Noller KL; Roach N; Runowicz C; Saslow D
Obstet Gynecol; 2004 Feb; 103(2):304-9. PubMed ID: 14754700
[TBL] [Abstract][Full Text] [Related]
10. The evaluation of human papillomavirus genotyping in cervical liquid-based cytology specimens; using the Roche Linear Array HPV genotyping assay.
Jamison J; Wilson RT; Carson J
Cytopathology; 2009 Aug; 20(4):242-8. PubMed ID: 19291176
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of combining testing for p16 protein and human papillomavirus (HPV) in cervical carcinoma screening.
Ekalaksananan T; Pientong C; Sriamporn S; Kongyingyoes B; Pengsa P; Kleebkaow P; Kritpetcharat O; Parkin DM
Gynecol Oncol; 2006 Oct; 103(1):62-6. PubMed ID: 16494930
[TBL] [Abstract][Full Text] [Related]
12. Molecular testing of human papillomavirus in cervical specimens.
Gazzaz FB
Saudi Med J; 2007 Dec; 28(12):1810-8. PubMed ID: 18060207
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of liquid-based cytology specimens for the immunocytochemical study of p16 expression and human papillomavirus testing: a comparative study using simultaneously sampled histology materials.
Yoshida T; Fukuda T; Sano T; Kanuma T; Owada N; Nakajima T
Cancer; 2004 Apr; 102(2):100-8. PubMed ID: 15098254
[TBL] [Abstract][Full Text] [Related]
14. [Detection and typing of human papilloma virus by polymerase chain reaction and hybridization assay in cervical samples with cytological abnormalities].
Ergünay K; Misirlioğlu M; Firat P; Tuncer ZS; Tuncer S; Yildiz I; Ustaçelebi S
Mikrobiyol Bul; 2008 Apr; 42(2):273-82. PubMed ID: 18697425
[TBL] [Abstract][Full Text] [Related]
15. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus.
Dalstein V; Merlin S; Bali C; Saunier M; Dachez R; Ronsin C
J Virol Methods; 2009 Mar; 156(1-2):77-83. PubMed ID: 19041893
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma.
Dehn D; Torkko KC; Shroyer KR
Cancer; 2007 Feb; 111(1):1-14. PubMed ID: 17219448
[TBL] [Abstract][Full Text] [Related]
17. Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets.
Getman D; Aiyer A; Dockter J; Giachetti C; Zhang F; Ginocchio CC
J Clin Virol; 2009 Jul; 45 Suppl 1():S49-54. PubMed ID: 19651369
[TBL] [Abstract][Full Text] [Related]
18. Cervical cancer screening in the 21st century: is it time to retire the PAP smear?
Wright TC
Clin Obstet Gynecol; 2007 Jun; 50(2):313-23. PubMed ID: 17513921
[TBL] [Abstract][Full Text] [Related]
19. Resolution of equivocal results with the Hybrid Capture II high-risk HPV DNA test: a cytologic/histologic review of 191 cases.
Knoepp SM; Kuebler DL; Wilbur DC
Diagn Mol Pathol; 2007 Sep; 16(3):125-9. PubMed ID: 17721319
[TBL] [Abstract][Full Text] [Related]
20. [Use of the Digene Hybrid Capture System for identification of the human papillomavirus (HPV-Human Papillomavirus) in women with cervical dysplasia].
Kwaśniewska A; Semczuk M; Sikorski M; Kraczkowski J
Przegl Lek; 1997; 54(12):848-50. PubMed ID: 9591452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
